Pandion Therapeutics set terms for its initial public offering on Monday with plans to offer 5.5 million shares priced at $16 to $18 each, according to a regulatory filing. The clinical-stage biotech, which specializes in treatments for autoimmune diseases, has applied to list on Nasdaq, under the ticker “NAND.” Goldman Sachs, Morgan Stanley, SVB Leerink and BMO Capital Markets are underwriting the deal. Proceeds will be used to fund clinical trials, R&D and for working capital and other general corporate purposes. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
- Kelley Blue Book: How does the Genesis G90 stand up to the Lincoln Continental? - September 29, 2020
- NerdWallet: Don’t assume travel insurance covers COVID-related claims: How to find the right provider - September 29, 2020
- NerdWallet: Will there be a Black Friday this year? The future of the big shopping day is unknown - September 29, 2020